NCT03575351 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 92
- group Id
- BG002
- value
- 184
- units
- Participants
- groups
- description
- 3 cycles of standard of care (SOC) salvage therapy (rituximab, dexamethasone, cytarabine and cisplatin \[R-DHAP\], rituximab, ifosfamide, carboplatin and etoposide \[R-ICE\], rituximab, gemcitabine, dexamethasone, and cisplatin \[R-GDP\]) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks
- id
- BG000
- title
- Standard of Care Arm
- description
- \[Lymphodepleting chemotherapy (LDC)\] Fludarabine IV (30 mg/m\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)
- id
- BG001
- title
- Liso-cel Arm
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 13.94
- value
- 54.2
- group Id
- BG001
- spread
- 12.61
- value
- 58.3
- group Id
- BG002
- spread
- 13.41
- value
- 56.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 79
- title
- Female
- measurements
- group Id
- BG000
- value
- 61
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 105
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 62
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 127
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 51
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 18
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 7
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 55
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 109
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 47
- title
- Not Collected or Reported
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 92
- group Id
- BG002
- value
- 184
- units
- Participants
- groups
- description
- 3 cycles of standard of care (SOC) salvage therapy (rituximab, dexamethasone, cytarabine and cisplatin \[R-DHAP\], rituximab, ifosfamide, carboplatin and etoposide \[R-ICE\], rituximab, gemcitabine, dexamethasone, and cisplatin \[R-GDP\]) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks
- id
- BG000
- title
- Standard of Care Arm
- description
- \[Lymphodepleting chemotherapy (LDC)\] Fludarabine IV (30 mg/m\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)
- id
- BG001
- title
- Liso-cel Arm
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 13.94
- value
- 54.2
- group Id
- BG001
- spread
- 12.61
- value
- 58.3
- group Id
- BG002
- spread
- 13.41
- value
- 56.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 79
- title
- Female
- measurements
- group Id
- BG000
- value
- 61
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 105
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 62
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 127
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 51
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 18
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 7
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 55
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 109
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 47
- title
- Not Collected or Reported
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle